Shareholder Class Action Filed Against Humana Inc. by The Law Firm of Schiffrin Barroway Topaz & Ke... ( RADNOR Pa. April 8 2008 /- The fo...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Shareholder Class Action Filed Against Humana Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

Date:4/8/2008

RADNOR, Pa., April 8, 2008 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:

Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Western District of Kentucky at Louisville, on behalf of all purchasers of securities of Humana Inc. (NYSE: HUM) ("Humana" or the "Company") between February 4, 2008 and March 11, 2008, inclusive (the "Class Period").

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin Barroway Topaz & Kessler, LLP (Darren J. Check, Esq. or Richard A. Maniskas, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@sbtklaw.com.

The Complaint charges Humana and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Humana is a health and supplemental benefits company, with approximately 11.5 million medical members. Humana is a full-service benefits solutions company, offering health and supplementary benefit plans for employer groups, government programs and individuals.

The Complaint alleges that, throughout the Class Period, defendants failed to disclose material adverse facts about the Company's financial well-being and prospects. Specifically, defendants failed to disclose or indicate the following: (1) that the Company's prescription drug plan costs had increased significantly; (2) that the Company was unable to accurately calculate the prescription drug costs of new members; and (3) that, as a result of the foregoing, the Company's statements about its financial well-being and future business prospects were lacking in any reasonable basis when made.

On March 12, 2008, the Company shocked investors when it announced that it was revising the earnings guidance that it had issued a month ea
'/>"/>

SOURCE Schiffrin Barroway Topaz & Kessler, LLP
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3
Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
3. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
4. United Medicorp, Inc.s Shareholders Approve All Proposals
5. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
6. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
7. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
8. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
9. Flextronics Shareholders and Solectron Stockholders Approve Acquisition
10. Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction
11. NOVT Corporations Board of Directors Terminates Shareholder Rights Plan

Post Your Comments:

[0] NICE guidelines ration affordable osteoporosis drugs [0] Menopause Often Means Worsening Cholesterol [0] China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 [1] New Board Gains Control of U.S. Shanghai Chemical Corporation [0] Surgery on beating heart thanks to robotic helping hand

Other Medicine News:Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 2 Health News:Cogdell Spencer Announces Commencement of Common Stock Offering 3 Health News:Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 2 Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 3 Health News:National study finds youth baseball-related injuries down 25 percent 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 3 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 4 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 2 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 3 Health News:Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer 4

Cogdell Spencer Announces Commencement of Common Stock Offering Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception National study finds youth baseball-related injuries down 25 percent More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer

Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2 Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3 Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5 Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2 Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1 Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2 Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1 Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2 Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3 Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4 Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1 Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2

[0] Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy [0] Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy [0] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program

Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5 Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6 Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 2 Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 3 Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 4 Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 5

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial

Medicine Products:

ALLEGRO Analyzer Zywave® II LUMIGAN® 7 mL REFRESH PLUS®

Shareholder Class Action Filed Against Humana Inc. by The Law Firm of Schiffrin Barroway Topaz & Ke...( RADNOR Pa. April 8 2008 /- The fo...),Health